Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (71)	12/17/1998 5:26:00 PM
From: nigel bates	Read Replies (1) \| Respond to of 946

Scott, The one truly compelling reason for CTIC is how cheap the stock is compared to its cash value. It crashes & burned last year when the previous lisofylline trial failed to pan out. There has been a minor rally from c.$2 per share, but I don't think we will see much more until they report some substantive progress on one of their compounds. The latest lisofylline news - "important imbalances in risk factors between the placebo and lisofylline groups may have resulted in the failure to achieve a significant effect on the study's primary endpoints of infection and mortality." - indicates why the jury continues to be out. They have some interesting stuff, and there is no premium in the stock price for any of it. IMO, worth a punt, but be prepared to hold for a while. nig